Targeting HIV-1 protease: A test of drug-design methodologies

West M.L. and Fairlie D.P. (1995) Targeting HIV-1 protease: A test of drug-design methodologies. Trends in Pharmacological Sciences, 16 2: 67-75. doi:10.1016/S0165-6147(00)88980-4


Author West M.L.
Fairlie D.P.
Title Targeting HIV-1 protease: A test of drug-design methodologies
Journal name Trends in Pharmacological Sciences   Check publisher's open access policy
ISSN 0165-6147
Publication date 1995
Sub-type Critical review of research, literature review, critical commentary
DOI 10.1016/S0165-6147(00)88980-4
Volume 16
Issue 2
Start page 67
End page 75
Total pages 9
Subject 3004 Pharmacology
3005 Toxicology
Abstract The proteinase of the human immunodeficiency virus (HIV-1 protease) is an obvious example of a receptor for which drug design methodologies have been successfully applied. In this article, Michael West and David Fairlie outline the specific progress made to date towards the rational design of protease inhibitors as anti-HIV drugs, and compare their pharmacological profiles. The rationale employed in designing protease inhibitors illustrates evolving trends in drug design, problems in comparing assay data, and obstacles to developing enzyme inhibitors into drugs.
Q-Index Code C1
Q-Index Status Provisional Code
Institutional Status Unknown

Document type: Journal Article
Sub-type: Critical review of research, literature review, critical commentary
Collection: Scopus Import
 
Versions
Version Filter Type
Citation counts: Scopus Citation Count Cited 162 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Tue, 26 Jul 2016, 04:37:45 EST by System User